Göran Ando


Born: 1949
Education: BSc Uppsala University, Medical degree Linköping University.

Experience: Göran Ando has over 30 years’ experience in the pharmaceutical industry. He began his career in 1978 as Medical Director of Pfizer AB and continued as head of clinical research with Pfizer International in the USA. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and also returned to Sweden as Chairman of the Astra Research Center. Between 1989 and 1995, he held a number of senior positions at Glaxo, including head of research and development for Glaxo Group Research. Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO and moved to the United States in 1997 to lead research and development with additional responsibilities for manufacturing, information technology, business development and mergers and acquisitions. During his eight-year tenure as head of research and development at Pharmacia / Pharmacia & Upjohn, 17 new drugs were approved by the FDA, prior to Pfizer’s acquisition of Pharmacia.

Dr. Ando was then named CEO of Celltech Group PLC in the UK, one of the most successful European biotechnology companies, until it was acquired by UCB Pharma in 2005.

Göran Ando was elected in 2005 as a board member of Novo Nordisk A / S, where he became Vice Chairman in 2006 and Chairman between 2013 and 2018.

Other positions: Göran Ando is Chairman of the Board of Eyepoint Pharmaceuticals (USA) and Tessa Therapeutics (Singapore) and a board member of EUSA Pharma (UK) and Selecta Biosciences (USA).

Holdings in Nanexa: 40 000 shares and 300 000 warrants of series TO 4 (2020/2023: 2).

Göran Ando is independent in relation to the company, the company management and the company’s major shareholders

Bengt Gustavsson


Born: 1962
Education: BSc in Pharmacy, Doctor of Medical Science (DMSc) Uppsala University. EUCOR / ECPM degree in Pharmaceutical Medicine from EUCOR universities in Basel, Freiburg and Strasbourg.

Experience: Bengt Gustavsson has many years’ experience from the pharmaceutical industry in Sweden and the Nordic countries, and has been Nordic Medical Director at Novartis Oncology, Nordic Clinical Research Director at Sanofi-Aventis, Nordic Medical Head of Celgene and Global Head of Medical Affairs på Oncopeptides. Bengt Gustavsson is a former reserve officer in the Swedish Air Force

Other positions: Medical Director at Nanexa since 2021. Owner and CEO of Sangus Jazz AB.

Holdings in Nanexa: 32,000 shares and 106,000 warrants of series TO 4 (2020/2023: 2).

Bengt Gustavsson is independent in relation to the company’s major shareholders but not independent in relation to the company and its management.

Urban Paulsson


Born: 1963
Education: Law degree, Lund University

Experience: Urban Paulsson has worked for more than 25 years in the pharmaceutical industry with various legal issues in a variety of roles, e.g. as General Counsel and Vice President Corporate Development at Camurus AB and General Counsel at Vitrolife AB. He has previously worked as a lawyer and Partner at the law firms Bird & Bird and Nordia.

In recent years, Urban has founded four biotechnology companies – Cinclus Pharma, Gesynta Pharma, Cormorant Pharmaceuticals and Buzzard Pharmaceuticals.

Cormorant was successfully sold to BMS 2016.

Other positions: Chairman of the Board of Evident Life AB, Gesynta Pharma AB, Buzzard Pharmaceuticals AB, MetaCurUm Biotech AB, Cavis Technologies AB, Brf Bellman AB, Cordivest AB and board members of Nylof Holding AB and Urban Paulsson AB. Urban is active as an investor in life science.

Holdings in Nanexa: 60 000 shares and 106 000 warrants of series TO 4 (2020/2023: 2), via companies.

Urban Paulsson is independent in relation to the company, the company management and the company’s major shareholders, respectively.

Eva Nilsagård

BOARD MEMBER since 2021

Born: 1964
Education: BSc in Business Administration and Executive MBA from the School of Business, Economics and Law at the University of Gothenburg

Experience: Eva Nilsagård has over 30 years’ experience in senior positions, primarily in the automotive and medtech/biotech industries, such as CFO for Vitrolife, Plastal Industri and OptiGroup, Senior VP Strategy & Business development at Volvo Group Sales & Marketing EMEA, and senior positions in AstraZeneca and AB Volvo. She is Founder and CEO of Nilsagård Consulting AB, where in recent years she has held several interim positions as CEO and CFO. Professional Board career with involvement in listed, private and state-owned companies where she, among other things, contributed expertise in audit committee work and corporate governance and was involved in several IPOs. For the past ten years, Eva has acted as a mentor to several young female leaders.

Other positions: Board member of Addlife AB, Bufab AB (publ), Hansa Biopharma AB, Nimbus Group AB, Irras AB, Xbrane Biopharma AB and AB Svensk Exportkredit, Chairman of the Board of Spermosens AB and President and Board member of Nilsagård Consulting AB.

Holdings in Nanexa: 60 000 shares, via companies

Magnus Westgren


Born: 1950
Education: BSc in Medicine and Doctor of Medicine (MD) at Lund University. Associate professor at Karolinska Institutet.

Experience: Magnus Westgren has previously been Head of Obstetrics at Karolinska University Hospital and has been a professor at Karolinska Institutet since 2006. Postdoctoral work 1984–1985 at the Department of Obstetrics and Gynecology at Women’s Hospital University of Southern California. Magnus has also been a scientific consultant and advisor to the National Board of Health and Welfare, supervisor for 30 doctoral students and has published more than 300 scientific papers. He is a Fellow of the Royal College of Obstetricians and Gynecologists.

Other positions: Chairman of the Board of MedSciNet AB, Board member of BoostPharma ApS and Westknow AB and Senior Professor at Karolinska Institutet.

Holdings in Nanexa: 253 464 shares and 106,000 warrants of series TO 4 (2020/2023: 2). Related party holdings: 700 shares.

Magnus Westgren is independent in relation to the company, the company management and the company’s major shareholders, respectively.

Birgit Stattin Norinder

BOARD MEMBER since 2021

Born: 1948
Education: BSc in Pharmacy, MSc of Pharmacy (MPharm), Uppsala University

Experience: Birgit Stattin Norinder has extensive experience from pharma and biotech companies in Sweden, the USA and the United Kingdom. She has led several Research and Development departments and has been behind a number of new and approved drugs. Birgit has been CEO and Chairman of Prolifix Ltd, Senior Vice President Worldwide Development at Pharmacia & Upjohn and Director International Regulatory Affairs at Glaxo Group Research Ltd. Birgit has also held a number of positions as a Board member and Chairman of European biotechnology companies.

Other positions: Board member of AddLife AB, Jettesta AB and Oasmia Pharmaceutical AB.

Holdings in Nanexa: 20 000 shares

Birgit Stattin Norinder is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.

Richard Davis

Board member since 2022

Born: 1973
Education: Doctor of Philosophy (PhD) in Pharmacology and Bachelor of Science in Biochemical Pharmacology from University of Leicester, UK

Experience: Richard has many years of experience as an investor and executive in pharmaceutical development companies. Richard previous experience i.a. from positions as Global Oncology Venture and Transaction Lead at Johnson and Johnson, CEO of European clinical stage biotechnology company Trino Therapeutics, and Investment Manager and responsible for direct healthcare investments and venture capital funds at Wellcome Trust. During his time at Wellcome Trust, Richard was on the board of a number of biotech companies and worked closely with management teams on strategy, financing and exits via M&A and public listings.

Other positions: Chief Business and Operating Officer at Swiss oncology company Nouscom AG

Holdings in Nanexa:

Richard Davis is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.